catalysts

Biotech’s breakout is a catalyst trade, not a new market leader

Biotech’s sharp outperformance is real, but the rally is rewarding profitable franchises and identifiable catalysts rather than lifting the entire sector. The better opportunity is selective exposure to de-risked pipelines, not indiscriminate bets on biotech as technology’s replacement.